医学临床研究
  2025年7月11日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (9): 1324-1327    DOI: 10.3969/j.issn.1671-7171.2021.09.013
  论著 本期目录 | 过刊浏览 | 高级检索 |
三阴性乳腺癌组织中p53表达对患者预后的影响
杨喜佳1, 刘琪2**
1.西安高新医院普外科,陕西 西安 710061;
2.杨凌示范区医院肝胆普外科,陕西 杨凌 712100
Effect of p53 Expression on Prognosis in Triple Negative Breast Cancer
YANG Xi-jia, LIU Qi
Department of General Surgery, Xi'an High-Tech Hospital, Xi'an 710061
全文: PDF (1423 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨p53在三阴性乳腺癌中的表达情况及其与预后的关系。【方法】选取本院收治的可手术三阴性乳腺癌患者79例,取术中新鲜癌组织及癌旁组织,采用免疫组化法检测p53表达情况。对患者进行随访,观察患者复发转移情况及总生存期(OS),并分析复发转移、OS与p53表达的关系。【结果】三阴性乳腺癌中p53的表达率高达40.51%(32/79),高于癌旁组织的11.39%(9/79),且差异有显著性(P<0.05)。p53高表达组淋巴结分期(N)N3期比例及组织学Ⅲ级比例高于p53低表达组(均P<0.05)。随访时间36~60(49.6±4.9)个月,共70例患者得到随访,9例失访。共17例患者复发,高表达组复发率显著高于低表达组,且差异有显著性(P<0.05)。共11例患者转移,高表达组转移率显著高于p53低表达组,且差异有显著性(P<0.05)。随访期内有17例(24.28%)死亡。Kaplan-Meier法并Log-rank检验结果显示,p53高表达的三阴性乳腺癌患者OS较p53低表达的三阴性乳腺癌患者缩短(P<0.05)。多因素COX结果显示,肿瘤大小、淋巴结分期、p53表达、组织学分级是影响三阴性乳腺癌患者死亡的独立预后因素(P<0.05)。【结论】三阴性乳腺癌中p53表达上调,且高p53的患者预后不良,复发转移及死亡风险增加。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
杨喜佳
刘琪
关键词 乳腺肿瘤/病理学受体,erbB-2雌激素类孕酮肿瘤抑制蛋白质p53预后    
Abstract:【Objective】To explore the expression of p53 in triple-negative breast cancer and its relationship with prognosis. 【Methods】A total of 79 patients with operable triple-negative breast cancer treated in our hospital were selected. Fresh cancer tissues and adjacent tissues were collected during operation, and p53 expression was detected by immunohistochemistry. The patients were followed up to observe the recurrence, metastasis and overall survival (OS). The relationship of p53 expression with recurrence, metastasis and OS was analyzed. 【Results】The positive expression rate of p53 (40.51%) in triple-negative breast cancer was higher than that in adjacent tissues (11.39%), and the difference was statistically significant(P<0.05).The proportion of N3 and grade Ⅲ in p53 high expression group was higher than that in p53 low expression group (both P<0.05). The follow-up time was 36-60 (49.6 ± 4.9) months. A total of 70 patients were followed up and 9 were lost to follow-up. A total of 17 patients relapsed. Of which, the recurrence rate in the p53 high expression group was significantly higher than that in the p53 low expression group, and the difference was statistically significant(P<0.05). A total of 11 patients had metastasis. The metastasis rate in the p53 high expression group (32.14%) was significantly higher than that in the p53 low expression group, and the difference was statistically significant(P<0.05). During the follow-up period, 17 patients died. Kaplan-Meier method and Log-rank test results showed that patients with triple-negative breast cancer plus high expression of p53 had shorter OS than those patients with triple-negative breast cancer plus low expression of p53 (P<0.05). Multivariate COX results showed that tumor size (T), lymph node stage (N), p53 expression, and histological grade were independent prognostic factors affecting the death of triple-negative breast cancer patients (P<0.05). 【Conclusion】The p53 expression is up-regulated in triple negative breast cancer, and patients with high p53 expression have a poor prognosis and high risk of recurrence, metastasis, and death.
Key wordsBreast Neoplasms/PA    Receptor, ErbB-2    Estrogens    Progesterone    Tumor Suppressor Protein p53    Prognosis
收稿日期: 2020-10-16     
中图分类号:  R737.9  
基金资助:西安市卫生健康委员会科研项目(编号:2020yb61)
通讯作者: **E-mail:67998106@qq.com   
引用本文:   
杨喜佳, 刘琪. 三阴性乳腺癌组织中p53表达对患者预后的影响[J]. 医学临床研究, 2021, 38(9): 1324-1327.
YANG Xi-jia, LIU Qi. Effect of p53 Expression on Prognosis in Triple Negative Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1324-1327.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.09.013     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I9/1324
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn